Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Y-mAbs Therapeutics Inc has a consensus price target of $18.07 based on the ratings of 16 analysts. The high is $26 issued by Canaccord Genuity on August 13, 2024. The low is $7 issued by Morgan Stanley on March 5, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., B of A Securities, and Truist Securities on March 21, 2025, March 5, 2025, and March 5, 2025, respectively. With an average price target of $14 between HC Wainwright & Co., B of A Securities, and Truist Securities, there's an implied 191.67% upside for Y-mAbs Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/21/2025 | Buy Now | 150% | HC Wainwright & Co. | Robert Burns41% | $22 → $12 | Maintains | Buy | Get Alert |
03/05/2025 | Buy Now | 150% | B of A Securities | Alec Stranahan33% | $14 → $12 | Maintains | Neutral | Get Alert |
03/05/2025 | Buy Now | 275% | Truist Securities | Nicole Germino48% | $21 → $18 | Maintains | Buy | Get Alert |
03/05/2025 | Buy Now | 45.83% | Morgan Stanley | Michael Ulz60% | $11 → $7 | Maintains | Underweight | Get Alert |
01/13/2025 | Buy Now | 358.33% | HC Wainwright & Co. | Robert Burns41% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
12/11/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns41% | — | Reiterates | Buy → Buy | Get Alert |
12/05/2024 | Buy Now | 254.17% | Brookline Capital | Kemp Dolliver32% | → $17 | Initiates | → Buy | Get Alert |
11/18/2024 | Buy Now | 379.17% | Oppenheimer | Jeff Jones32% | → $23 | Initiates | → Outperform | Get Alert |
11/15/2024 | Buy Now | 358.33% | HC Wainwright & Co. | Robert Burns41% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
09/10/2024 | Buy Now | 379.17% | Wedbush | David Nierengarten61% | $23 → $23 | Reiterates | Outperform → Outperform | Get Alert |
09/09/2024 | Buy Now | 316.67% | Cantor Fitzgerald | Li Watsek40% | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
08/16/2024 | Buy Now | 316.67% | Cantor Fitzgerald | Li Watsek40% | → $20 | Initiates | → Overweight | Get Alert |
08/13/2024 | Buy Now | 441.67% | Canaccord Genuity | Bill Maughan19% | $26 → $26 | Maintains | Buy | Get Alert |
08/13/2024 | Buy Now | 129.17% | Morgan Stanley | Michael Ulz60% | $12 → $11 | Maintains | Underweight | Get Alert |
08/13/2024 | Buy Now | 358.33% | HC Wainwright & Co. | Robert Burns41% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
08/13/2024 | Buy Now | 420.83% | BMO Capital | Etzer Darout45% | $26 → $25 | Maintains | Outperform | Get Alert |
07/11/2024 | Buy Now | 379.17% | Jones Trading | Justin Walsh40% | → $23 | Initiates | → Buy | Get Alert |
06/28/2024 | Buy Now | 337.5% | Truist Securities | Nicole Germino48% | → $21 | Initiates | → Buy | Get Alert |
05/13/2024 | Buy Now | 358.33% | HC Wainwright & Co. | Robert Burns41% | $21 → $22 | Maintains | Buy | Get Alert |
03/06/2024 | Buy Now | 358.33% | HC Wainwright & Co. | Robert Burns41% | $21 → $22 | Maintains | Buy | Get Alert |
03/04/2024 | Buy Now | 441.67% | Canaccord Genuity | Bill Maughan19% | $22 → $26 | Maintains | Buy | Get Alert |
03/04/2024 | Buy Now | 441.67% | BMO Capital | Etzer Darout45% | $16 → $26 | Maintains | Outperform | Get Alert |
02/20/2024 | Buy Now | 337.5% | HC Wainwright & Co. | Robert Burns41% | $11 → $21 | Maintains | Buy | Get Alert |
11/15/2023 | Buy Now | 129.17% | HC Wainwright & Co. | Robert Burns41% | → $11 | Reiterates | Buy → Buy | Get Alert |
08/22/2023 | Buy Now | 45.83% | JP Morgan | Tessa Romero61% | $8 → $7 | Maintains | Underweight | Get Alert |
08/14/2023 | Buy Now | 4.17% | Morgan Stanley | Michael Ulz60% | $7 → $5 | Maintains | Underweight | Get Alert |
08/14/2023 | Buy Now | 129.17% | HC Wainwright & Co. | Robert Burns41% | → $11 | Reiterates | Buy → Buy | Get Alert |
07/25/2023 | Buy Now | 358.33% | Canaccord Genuity | William Plovanic56% | $21 → $22 | Maintains | Buy | Get Alert |
06/07/2023 | Buy Now | 337.5% | Canaccord Genuity | William Plovanic56% | → $21 | Reiterates | Buy → Buy | Get Alert |
05/15/2023 | Buy Now | 150% | B of A Securities | Alec Stranahan33% | $6 → $12 | Maintains | Neutral | Get Alert |
05/10/2023 | Buy Now | 45.83% | Morgan Stanley | Michael Ulz60% | $4 → $7 | Maintains | Underweight | Get Alert |
05/10/2023 | Buy Now | 170.83% | Wedbush | David Nierengarten61% | $5 → $13 | Upgrade | Neutral → Outperform | Get Alert |
05/09/2023 | Buy Now | 337.5% | Canaccord Genuity | William Plovanic56% | $18 → $21 | Maintains | Buy | Get Alert |
04/04/2023 | Buy Now | 129.17% | HC Wainwright & Co. | Robert Burns41% | $19 → $11 | Maintains | Buy | Get Alert |
04/03/2023 | Buy Now | — | Guggenheim | Etzer Darout45% | — | Downgrade | Buy → Neutral | Get Alert |
04/01/2023 | Buy Now | 25% | B of A Securities | Alec Stranahan33% | → $6 | Maintains | Neutral | Get Alert |
03/31/2023 | Buy Now | 275% | Canaccord Genuity | William Maughan71% | $20 → $18 | Maintains | Buy | Get Alert |
01/30/2023 | Buy Now | 170.83% | BMO Capital | Etzer Darout45% | $12 → $13 | Maintains | Outperform | Get Alert |
01/27/2023 | Buy Now | — | Morgan Stanley | Michael Ulz60% | — | Downgrade | Equal-Weight → Underweight | Get Alert |
01/05/2023 | Buy Now | — | Cowen & Co. | Joseph Thome34% | — | Downgrade | Outperform → Market Perform | Get Alert |
12/15/2022 | Buy Now | 25% | B of A Securities | Alec Stranahan33% | $5 → $6 | Maintains | Neutral | Get Alert |
12/02/2022 | Buy Now | 4.17% | B of A Securities | Alec Stranahan33% | $23 → $5 | Downgrade | Buy → Neutral | Get Alert |
11/01/2022 | Buy Now | 150% | BMO Capital | Etzer Darout45% | $29 → $12 | Maintains | Outperform | Get Alert |
10/31/2022 | Buy Now | 462.5% | Canaccord Genuity | William Maughan71% | $35 → $27 | Maintains | Buy | Get Alert |
10/31/2022 | Buy Now | 66.67% | Morgan Stanley | Michael Ulz60% | $17 → $8 | Maintains | Equal-Weight | Get Alert |
10/31/2022 | Buy Now | 25% | Wedbush | David Nierengarten61% | → $6 | Downgrade | Outperform → Neutral | Get Alert |
10/31/2022 | Buy Now | 295.83% | HC Wainwright & Co. | Robert Burns41% | $63 → $19 | Maintains | Buy | Get Alert |
10/31/2022 | Buy Now | 45.83% | JP Morgan | Tessa Romero61% | $16 → $7 | Downgrade | Neutral → Underweight | Get Alert |
09/09/2022 | Buy Now | 254.17% | Morgan Stanley | Michael Ulz60% | $15 → $17 | Maintains | Equal-Weight | Get Alert |
06/24/2022 | Buy Now | 462.5% | BMO Capital | Etzer Darout45% | → $27 | Initiates | → Outperform | Get Alert |
The latest price target for Y-mAbs Therapeutics (NASDAQ:YMAB) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $12.00 expecting YMAB to rise to within 12 months (a possible 150.00% upside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for Y-mAbs Therapeutics (NASDAQ:YMAB) was provided by HC Wainwright & Co., and Y-mAbs Therapeutics maintained their buy rating.
The last upgrade for Y-mAbs Therapeutics Inc happened on May 10, 2023 when Wedbush raised their price target to $13. Wedbush previously had a neutral for Y-mAbs Therapeutics Inc.
The last downgrade for Y-mAbs Therapeutics Inc happened on April 3, 2023 when Guggenheim changed their price target from N/A to N/A for Y-mAbs Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Y-mAbs Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Y-mAbs Therapeutics was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.
While ratings are subjective and will change, the latest Y-mAbs Therapeutics (YMAB) rating was a maintained with a price target of $22.00 to $12.00. The current price Y-mAbs Therapeutics (YMAB) is trading at is $4.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.